At the next congress of the American Society of Clinical Oncoly (ASCO), a major annual meeting for clinical research and innovation in oncology, Nanobiotix will provide an update on its preclinical and clinical developments in various solid tumors and therapeutic combinations: presentation of very promising results from an unprecedented phase II study in rectal cancer. Nanobiotix will also review progress from the ongoing global Phase III study in high-risk elderly patients with locally advanced head and neck cancer.
Nanobiotix is currently conducting a dozen clinical trials, worldwide, in cooperation with, in particular, the Institut Curie, the Gustave Roussy Institute, and the MD Anderson Cancer Center (United States).
Clinical trials (Phases I, II, III)
Phase I: small-scale testing of the molecule on humans to assess its safety, tolerance, metabolic and pharmacological properties.
Phase II: evaluation of tolerance and efficacy on several hundred patients to identify side effects.
Phase III: evaluation of the overall benefit/risk ratio with several thousand patients.